secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK:        0001356576
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001356576-23-000031
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Supernus Q1 revenue flat at $153.8M; Qelbree sales triple to $25.8M; raises FY 2023 guidance
--------------------------------------------------------------------------------

- Q1 total revenues $153.8M (+1% YoY); GAAP operating earnings $5.2M vs $2.0M; net earnings $16.9M ($0.29/sh) vs $25.6M ($0.43/sh).
- Qelbree net sales $25.8M (vs $8.3M YoY); GOCOVRI $26.0M (+15%); Trokendi XR fell 45% to $34.8M due to generic entry.
- Excluding Trokendi XR, net product sales up 25% YoY; total IQVIA Qelbree prescriptions rose 14% QoQ to 134,530.
- Raising FY 2023 GAAP operating loss guidance to $(30)-$(10)M from $(40)-$(10)M; non-GAAP operating earnings raised to $75-100M.
- Repaid $402.5M of 0.625% convertible notes due 2023 on April 1; credit line balance of $78.4M to be fully repaid by Q2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356576/000135657623000031/0001356576-23-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356576/000135657623000031/supn-20230509.htm
  HTML page:      https://secwatch.observer/filing/0001356576-23-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer